Süleyman Buyukberber

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Elevated Serum CA-125 Levels in Hemodialysis Patients with Peritoneal, Pleural, or Pericardial Fluids

Alper Sevinç, Süleyman Buyukberber, Hacı Mehmet Türk et al. · Gynecologic Oncology · 2000 · 87 citations

Medicine, Nephrology, Dialysis +6

Outcome of Newly Diagnosed Glioblastoma Patients Treated by Radiotherapy plus Concomitant and Adjuvant Temozolomide: A Long-Term Analysis

Özge Petek Erpolat, Müge Akmansu, Fatih Göksel et al. · Tumori Journal · 2009 · 71 citations

Medicine, Oncology, Radiation Oncology +17

Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

Şuayib Yalçın, Rüçhan Uslu, Faysal Dane et al. · Oncology · 2013 · 70 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus

Gursel Ak, Süleyman Buyukberber, Alper Sevinç et al. · Journal of Diabetes and its Complications · 2001 · 61 citations

Medicine, Endocrinology, Internal Medicine +15